Basic research in HIV vaccinology is hampered by reductionist thinking

Marc H. V. Van Regenmortel*
Stellenbosch Institute of Advanced Study, Wallenberg Research Center at Stellenbosch University, Stellenbosch, South Africa

INTRODUCTION

Before it was recognized that the vast majority of epitopes in proteins are discontinuous, i.e., composed of surface residues originating from distant parts of the protein sequence, short peptide segments of viral proteins able to react with antiprotein antibodies were considered to be continuous epitopes mimicking the antigenicity of the protein. This led to the expectation that if such peptides could be made to adopt the 3D structure found in the GERMLINE version of the matured Abs.

This review describes the structure-based reverse vaccinology approach aimed at developing vaccine immunogens capable of inducing antibodies that broadly neutralize HIV-1. Some basic principles of protein immunochemistry are reviewed and the implications of the extensive polyspecificity of antibodies for vaccine development are underlined. Although it is natural for investigators to want to know the cause of an effective immunological intervention, the classic notion of causality is shown to have little explanatory value for a system as complex as the immune system, where any observed effect always results from many interactions between a large number of components. Causal explanations are reductive because a single factor is singled out for attention and given undue explanatory weight on its own. Other examples of the negative impact of reductionist thinking on HIV vaccine development are discussed. These include (1) the failure to distinguish between the chemical nature of antigenicity and the biological nature of immunogenicity, (2) the belief that when an HIV-1 epitope is reconstructed by rational design to better fit a neutralizing monoclonal antibody (mAb), this will produce an immunogen able to elicit Abs with the same neutralizing capacity as the Ab used as template for designing the antigen, and (3) the belief that protection against infection can be analyzed at the level of individual molecular interactions although it has meaning only at the level of an entire organism. The numerous unsuccessful strategies that have been used to design HIV-1 vaccine immunogens are described and it is suggested that the convergence of so many negative experimental results justifies the conclusion that reverse vaccinology is unlikely to lead to the development of a preventive HIV-1 vaccine. Immune correlates of protection in vaccines have not yet been identified because this will become feasible only retrospectively once an effective vaccine exists. The finding that extensive antibody affinity maturation is needed to obtain mature anti-HIV-1 Abs endowed with a broad neutralizing capacity explains why antigens designed to fit matured Abs are not effective vaccine immunogens since these are administered to naive recipients who possess only B-cell receptors corresponding to the germline version of the matured Abs.

Keywords: antibody affinity maturation, antibody polyspecificity, discontinuous protein epitopes, HIV vaccines, rational vaccine design, reductionism, reverse vaccinology, systems biology

*Correspondence: Marc H. V. Van Regenmortel, CNRIS, UMR7242 – Institut de Recherche de l’Ecole de Biotechnologie de Strasbourg, Université de Strasbourg, Illkirch 67400, France. e-mail: vanregen@unistra.fr

doi: 10.3389/fimmu.2012.00194

www.frontiersin.org

July 2012 | Volume 3 | Article 194 | 5
immunogenicity, it became generally accepted that the prospects of developing effective synthetic peptide vaccines were very poor.

In the present review, it will be argued that many of the impediments that prevented the development of synthetic peptide vaccines in the past are responsible for the lack of success observed in current attempts to design HIV-1 vaccines based on the 3D structure of more complex discontinuous epitopes.

Arguments will be presented that the failure to develop an HIV-1 vaccine by rational design is mainly due to the underlying reductionist thinking that pervades much basic research in immunology and vaccinology. A reductionist mindset obscures the fundamental divide between antigenicity and immunogenicity, i.e., between the chemical nature of antigen–antibody recognition processes and the biological nature of the immunogenic processes that allow a viral antigen to give rise to a protective immune response in a competent host.

**Antibody Polyspecificity and the Relational Nature of Epitopes and Paratopes**

The regions of antigen molecules recognized by antibodies are called epitopes while the regions of antibodies that bind to epitopes are called paratopes. Both regions are usually identified by solving the 3D structure of antigen–antibody complexes and determining which amino acids in the two partners make contact with each other (Sandberg and Mariuzza, 2002). When a paratope is defined solely in terms of residues that make contact with an epitope, it is difficult to account for the observation that the binding activity of an antibody often depends on structural features distant from the paratope itself (Schulbach et al., 1993; Chatellier et al., 1996). Similarly, residues in the antigen that are not in contact with the antibody may be able to affect the binding process, for instance by influencing the conformation or stability of the free form of the protein or by participating in long-range allosteric effects. Complex formation is driven by the free energy change associated with the binding process, and residues away from the contact regions are often able to contribute to this free energy change as demonstrated by the changes in affinity and specificity that result when these residues are mutated (Greenspan and Di Cera, 1999). Mutational studies have also shown that not all contact residues contribute to the interaction energy, confirming that epitopes defined structurally differ from epitopes identified in functional assays (Cunningham and Wells, 1993). Furthermore, the structures visualized in antigen–antibody complexes may differ from the structures of the binding sites in the free molecules, before the processes of mutual adaptation and induced fit that often occur when the two partners interact (Wilson and Stanfield, 1994; Bosshard, 2001; Kim et al., 2011). As a result the structure of an epitope bound to an MAb may not correspond to the structure that is recognized by B-cell receptors (BCRs) during the immunization process and is presumed to be required in a vaccine. It is also known that residues in the antigen that are not in contact with paratope residues may be able to modulate the immunogenic activity of epitopes (Moudgil et al., 1998). It was also found that the sensitivity to neutralization of HIV-1 strains that harbor the core epitope recognized by sHAb 4E10 was modulated by amino acid substitutions elsewhere in the viral envelope (Gray et al., 2008). All these observations are consistent with the view that epitopes and paratopes are fuzzy binding sites devoid of clear-cut structural boundaries (Van Regenmortel, 1998a).

Specificity has been defined by Medawar and Medawar (1978) as the complementary relationship existing between an agent and something acted on, which arises from the stereochemical complementarity found between such partners as antigen and antibody, enzyme and substrate, or receptor and ligand. In addition to being defined as a measure of goodness of fit between paratope and epitope, antibody specificity can also be viewed as resulting from the capacity of an antibody to discriminate between two or more antigens (Day, 1990, p. 291; Frank, 2002, p. 42).

Antibodies recognize complementary antigens through the extremely versatile binding sites of immunoglobulin (Ig) molecules which are able to recognize virtually every molecular structure (Nezlin, 1994; Wucherpfennig et al., 2007). The Ig binding site consists of 50–70 hypervariable residues distributed over the six complementarity-determining regions (CDRs) of the variable domains of the heavy and light Ig chains. Each Ig binding site contains numerous overlapping and non-overlapping paratope subsites of 10–20 residues, each approximately 2800 Å² in area, that are able to bind to different antigens. The surface of one paratope corresponds to only 20–35% of the total surface encompassed by the CDRs of an Ig molecule (Denisova et al., 2010). An Ig molecule may sometimes harbor two non-overlapping paratopes, which will allow it to bind simultaneously to two small antigens (Richards et al., 1975; Bhattacharjee and Claudemans, 1978; Eisen and Chakraborty, 2010). A more common situation is that paratope subsites present in an Ig molecule at least partly overlap which prevents two different antigens from binding simultaneously to the same Ig. The presence of multiple paratopes in Ig molecules means that antibody molecules are always polyspecific (Frank, 2002).

The polyspecificity of antibodies is also demonstrated by their ability to bind large numbers of small peptides possessing limited sequence similarity and by the fact that many residues of an epitope can be replaced by any other amino acid without impairing the epitope’s antigenic reactivity (Getzeff et al., 1988; Geyser et al., 1988). When peptide libraries are tested for their ability to bind Mabs raised against a protein, it is usually found that many peptides that bind Ig residues situated outside the paratope region show little sequence similarity with the target antigen. Such peptides are therefore poor mimics of any epitope of the native protein although they are often referred to as mimotopes (Van Regenmortel, 2009a; Denisova et al., 2010; Irving et al., 2001, 2010).

The fact that every antibody molecule always harbors numerous paratopes, allowing it to bind many related or unrelated epitopes, was recognized as soon as myeloma proteins and Mabs became available and their specificity could be analyzed (for a review, see Eisen and Chakraborty, 2010). It is therefore astonishing that the implications of antibody polyspecificity for vaccine development were pointed out only recently (Van Regenmortel, 2011a, 2012) since the degeneracy of the immune system has been known for many years (Sterling et al., 1985; Parnes, 2004; Wucherpfennig et al., 2007).

The entire surface of proteins harbors a large number of overlapping discontinuous epitopes which can be identified only
when many Mabs reacting with the protein have been isolated. Discontinuous epitopes consist of two to five short linear stretches of residues that are distant in the protein sequence but are brought together by the folding of the peptide chain. Since the number of Mabs available for each protein is usually limited, it may seem that antigenicity is located in discrete epitope regions rather than forming an antigenic continuum at the surface of the protein (Van Regenmortel, 2009b). Since discontinuous epitopes cannot be isolated in active form from the protein in which they are embedded, it is impossible to study their capacity to act as effective vaccine immunogens on their own. The intact, native protein must always be used as immunogen and this inevitably produces a heterogeneous response against the numerous epitopes present in the protein (Van Regenmortel, 2012).

A second type of protein epitope called a continuous epitope is defined as any linear peptide region of the protein, usually 5-8 residues long, that is able to cross-react with antibodies raised against the protein. Continuous epitopes usually do not exist as individual, discrete binding or immunogenic sites in the native protein, and only some of their residues may be present at the surface of the protein where they are usually part of discontinuous epitopes (Chen et al., 2009).

The same residues at the surface of a protein may contribute to several overlapping discontinuous epitopes recognized by different antibodies that present no similarity in their CDRs. As illustrated in Figure 1 for two lysozyme antibodies, two Mabs recognizing what appears to be a very similar epitope may bind through completely different paratopes that show no similarity in chemical bonding pattern. Epitopes and paratopes are in fact relational entities that can be defined only by their mutual complementarity since they depend on each other to acquire a recognizable identity. Epitopes and paratopes are thus not intrinsic structural features of antigens and antibodies, respectively, because they do not exist as specific sites in the absence of a complementarity nexus between two partners (Van Regenmortel, 2009b). This means, for instance, that the two paratopes illustrated in Figure 1 do not actually recognize the same epitope. In view of the relational nature of epitopes, the number of epitopes in a protein is equal to the number of different Mabs that can be raised against it. This number was found to be 115 for the insulin molecule (Schroer et al., 1983) and more than a thousand for the BLyS molecule (Edwards et al., 1993). Another consequence of this relational nexus is that analyzing the antigenicity of a protein is equivalent to analyzing the size of the immunological repertoire of the host immunized with the protein.

Antibodies are often given names that suggest they are specific for particular proteins or antigenic sites which always harbor numerous epitopes. This practice can lead to confusion since an antibody cannot be specific for a multipletic protein as a whole but only for one of its epitopes. There is therefore no clear answer to the question whether an Mab or a polyclonal antiserum is the more specific reagent since it depends on which antigens the investigator is trying to differentiate (Van Regenmortel, 1998a). An individual Mab is usually better able to discriminate between two cross-reactive epitopes than a polyclonal antiserum, although the antiserum tends to have greater specificity for a multipletic protein. The reason for this is that the many antibodies in an antiserum which recognize the same protein through separate epitopes give rise to an additive specificity effect. Since each polyspecific Ab in the polyclonal serum cross-reacts with a large number of epitopes that are different for each Ab, the collective cross-reactive potential of the antiserum is diluted out which leads to the separate cross-reactivities of the different antibodies being masked (Til-mage, 1959; Richards et al., 1975; Al Moudallal et al., 1982; Parnes, 2004). The ability of the immune system to specifically recognize a huge number of multipletic antigens is therefore not due to the existence of myriads of antibodies, each one recognizing a unique epitope present in only one antigen, but arises from the
combinatorial effect of several polyspecific antibodies recognizing separate epitopes on the same antigen (Wucherpfennig et al., 2007; Van Regenmortel, 2012).

CAUSATION AND EXPLANATION IN BIOLOGY AND IMMUNOLOGY

Philosophers usually describe the process of scientific explanation by the so-called deductive-nomological model which presents explanations as being logically deduced from one or other relevant law of nature (Klee, 1997; Psillos, 2002). For instance, the occurrence of an eclipse will be explained using Newton’s laws of universal gravitation together with certain initial conditions. Newton’s laws of motion apply to celestial bodies because they move in an interstellar vacuum, free from external interference. On Earth, the laws of Newtonian mechanics explain phenomena only if one adds a ceteris paribus (i.e., other things being equal) clause to rule out interfering forces such as electromagnetic forces (Cartwright, 1983). Newton’s laws have sometimes been blamed for leading scientists to expect that all explanations in science should be able to provide the precise predictions achievable in astronomy. In physics, there are many well-established laws that do lead to extremely reliable predictions and have given us a remarkable understanding of the physical universe. Unfortunately, this is not possible in biology for the simple reason that there are no universal laws in biology (Dugas, 1993). Causal explanations in terms of a single cause acting according to a law of nature are therefore not possible in the biological sciences.

Causation is a mode of event generation (Bunge, 2003) and causal relations are relations between successive events and not between two material objects or between a structure and an event. A biological event such as the binding reaction between an antibody and an antigen is thus not caused by the structure of the reactants. An antibody on its own possesses no causal efficacy in bringing about a biological activity such as infectivity neutralization which involves a tertiary relationship between antibody, pathogen, and host and always depends on numerous immunological and pathophysiological factors.

In biology, only contributory causes can be identified because a multiplicity of background conditions or factors are always involved in bringing about an effect (Van Regenmortel, 2002a). Because of synergy and various interference phenomena, there is also no linear relationship between the magnitude of one causal factor and the magnitude of a biological effect. Since any observed effect always results from the complex network of interactions and internal regulations that exist in every biological system, a single causal factor can never be presented as an explanation since it is not realistic to assume that the clause “other things being equal” is relevant when hundreds of background conditions contribute to an effect. In non-linear dynamic systems, the notion of causality has very little explanatory value (Berger, 1998; Wagner, 1999).

The immunogenicity of an epitope is a biological property, partly determined by its intrinsic chemical structure, which mainly depends on numerous extrinsic factors such as the host Ig repertoire, the presence of appropriate BCRs and T cell help, the use of adjuvants, the process of antibody affinity maturation, self-tolerance, and various cellular and regulatory mechanisms that exist only in the biological context of the immunized host. Explaining immunogenicity by referring to its multiple “causes” is therefore not helpful for controlling a process that is always influenced by a large number of interdependent and cooperative biological interactions.

The dictum “structure determines function” has many adepts among molecular biologists and often leads to the assumption that there is a linear causal pathway operating in biomolecules which links gene sequence to protein sequence and then to protein conformation, binding, and function. Such a pseudo-causal pathway appears to possess explanatory power because it is presented in a context-independent manner as if the chemical and cellular environment did not contribute to the process of protein folding or that the natural Darwinian selection process that led to the existence of a functional binding partner could be ignored (Van Regenmortel, 2002b). Such a hypothesized linear pathway is often presented as shown in Figure 2, which suggests that the unidirectional flow of genetic information that occurs from DNA to protein can be extended to the upper levels of biological complexity present in tissues, organs, and organisms. However, genes do not cause phenotypic characters and although they contribute to determining phenotypic traits, they do not act upon them. The prior state of a thing is also not the cause of its subsequent state, the caterpillar not being the cause of the butterfly (Mahnert and Bunge, 1997, p. 39). Although it has been said that to explain an event is to provide some information about its causal history (Psillos, 2002, p. 217), this does not mean that it is possible in immunology to demonstrate a single chain of successive causes and effects where each effect is itself the cause of a subsequent effect. The arrows pointing upwards in Figure 2 should thus not be interpreted as representing a single causal relation linking events occurring at different levels and providing an ultimate explanation of an immunological mechanism in terms of the genome. In the case of antibodies, Ig genes are randomly spliced together from gene segments and they undergo extensive somatic hypermutation following activation with antigen; antibody specificity is therefore determined by genetic mechanisms that are unique to the immune system.

There is no single upward causality chain linking all the levels of biological organization since the phenotypes observed at each level result from innumerable interactions between genetic, epigenetic, biochemical, and environmental factors. Although the misleading metaphors of codes, instructions, blueprints, and genetic programs continue to be used to describe the transmission of information from genes to proteins and phenotypes, the misconceptions that arise from the use of such terms are now generally recognized (Kay, 2000; Noble, 2008; Shapiro, 2009). The correspondence between a particular codon and the amino acid it codes for is usually described as being arbitrary or symbolic (Maynard-Smith, 2000). However, it is equally plausible that the code is not arbitrary but originated from the need to have a pattern of hydrophatic complementarity between the peptides specified by the sense and antisense strands of DNA molecules (Bialok, 1990; Trophsa et al., 1992). It is, indeed, remarkable that there is no exception to the rule that codons and anticodons always code for amino acids of opposite hydrophaticity, i.e., either hydrophilic or hydrophobic residues. This leads to peptides coded by the two DNA strands that tend to bind to each other. This
phenomenon explains why peptide analogs that retain the original hydropathic profile found in a continuous epitope are usually able to bind the same antibody although they possess little or no sequence similarity with the original epitope (Hanin et al., 1997; Van Regenmortel, 1998b).

The earlier confusion between the concepts of gene as a predictor of phenotypic characters and a developmental factor in ontogeny has been resolved (Bradie, 2003; Moss, 2003) and it is now evident that our considerable understanding of the mechanisms that allow genes to be translated into proteins has in fact given us very little insight on how phenotypic traits are produced in organisms (Oyama et al., 2001; Oyama, 2009). Although a gene-centric approach to understanding biological systems is still sometimes advocated (Brenner, 2010) it is generally accepted that there is no privileged level of determination in biology at any of the levels illustrated in Figure 2 and that both bottom up and top down determination can occur (Mahner and Bunge, 1997; Noble, 2012). Since the hierarchy of levels labeled "up" and "down" are actually metaphors (Noble, 2012), one can also refer to horizontal causation for describing the internal causal relations that operate within the boundaries of each of the different levels.

Any level in the hierarchy of biological complexity can be the starting point for a causal analysis, provided a certain initial state of affairs is considered to be in need of an explanation. However, the explanations must be framed in terms of network causality and they always have to consider the numerous factors that simultaneously influence the system in a given biological context. The upward and downward arrows in Figure 2 therefore represent only one factor among many others that contribute to the observed effect. In all cases, a causal link attributed to one particular factor or mechanism will have to be confirmed by subsequent experimentation which alters that factor since this is the only way to establish that the hypothetical cause elicits the predicted effect in a particular context (Van Regenmortel, 2007).

This means that in immunology, explanations in terms of causal links must be validated by experimental interventions and manipulations in order to satisfy Woodward’s (2003) requirement of “making things happen” (see Scientific Understanding Arises from the Ability to Successfully Manipulate the Immune System).

**REDUCTIONISM AND EMERGENCE IN IMMUNOLOGY**

The reductionist mindset is epitomized by the assertion of Crick (1966): "The ultimate aim of the modern movement in biology is to explain all biology in terms of physics and chemistry". Most biologists believe that organisms are composed solely of atoms and molecules without the participation of extraneous or spiritual forces, and they tend to take the view that biological systems can therefore be fully described and understood in terms of the physico-chemical properties of their constituent parts. In viral immunology, reductionist thinking leads to the expectation that both cell-mediated immunity (Zajac and Harrington, 2008) and antibody-mediated immunity to viruses (Neurath, 2008) will eventually be fully understood in terms of the molecular properties of T-cell receptors (TCRs), BCRs, antibodies, MHC molecules, cytokines, and various other cellular constituents.

It is true that methodological reductionism which dissects a biological system into its constituent parts has been extremely successful as a research strategy in molecular biology and immunology and this seems to accredit the view that biology is reducible to physics and chemistry. It is, therefore, somewhat paradoxical that in recent years biologists have become increasingly dissatisfied with the view that biological systems can be fully explained in a reductionist manner using physico-chemical principles. Misgivings about the validity of reductionist explanations in biology have been expressed at several international meetings (Bock and Goode, 1998; Van Regenmortel and Hull, 2002;
Van Regenmortel

Reductionist thinking in HIV vaccinology

Although such an analysis could be presented as a reduction of shift that no longer addresses a biological question, especially if it is debatable whether the analysis belongs to the biological field viral epitope and a paratope is described at the molecular level, the same reaction (Rose, 1998). When the interaction between a cause the other since both are descriptions at different levels of cal selection and superior fitness in the past (Rosenberg, 1994, p. 193; Van Regenmortel, 2002a). Using the terminology of Mayr (1961) biologists rely on so-called ultimate, historical causes rather than on proximate causes for explaining the functional activity of proteins (Laland et al., 2011).

Predicting the binding and functional activity of a protein de novo solely on the basis of its structure remains an impossible task. What is possible is to predict the probable activity of a protein by comparison with a structurally similar protein of known activity. In the case of antibodies, their multiple binding activities depend on the existence of a relational nexus with several unknown and unpredictable partners. Attempts to predict the neutralizing capacity of an antibody from its structure is even more unrealistic since it involves a ternary interaction between antibody, antigen, and host which is entirely context-dependent. Furthermore, it is impossible to instruct the immune system to produce polyclonal antibodies endowed with a synergistic neutralizing capacity, regardless of whether the structural correlates of that activity are known or unknown.

Vaccination as an immunological intervention is meaningful only at the level of an entire organism, since organs, tissues, or...
molecules cannot be vaccinated. The protection against disease which is the goal of all vaccination procedures therefore remains firmly anchored in the complexities of biological systems and cannot be reduced to the chemical level of a molecular interaction (Van Regenmortel, 2004b).

**HUMAN INTENTIONALITY AND RATIONAL DESIGN STRATEGIES**

The term “design” can be defined as the deliberate conceiving of an artificial, novel object or process by an intelligent being. The designer’s task is to pose and solve an inverse problem namely to imagine, using available knowledge, what would bring about a desired outcome (Bunge, 2003). In most cases, possible solutions must be tested by trial-and-error experiments until the preset goal is attained. This means that opposing rational design and empirical approaches in vaccine research (Karlsson-Hedestam et al., 2009) is fallacious since all scientific knowledge in the experimental sciences is derived from empirical testing that is necessarily planned and analyzed in a rational manner. One empirical research area that may justify additional investigations is the use of chemically inactivated HIV-1 immunogens. Several new methods are currently available to chemically inactivate the virus while retaining the functional integrity of the Env protein (Van Regenmortel, 2011a and references therein). It may thus be worthwhile to re-examine the potential value of a killed, genetically modified HIV-1 vaccine, provided the safety of such material has been established.

Doing something by design is synonymous to doing it intentionally, and human intentions tend to be perceived as the cause of all human behavior and actions. This often leads to the anthropomorphic fallacy that the behavior and activities of all living organisms can be understood in terms of intentions and purposes. Since all the individual components of a biological system contribute in an integrated manner to its functioning and survival, living organisms may give the impression of having been designed. However, biologists no longer use psychological notions of intentions, design, and purposes to explain biological functions since it is universally accepted that organisms were fashioned and shaped by the filter and pressure of Darwinian natural selection (Raue, 2002; Hanke, 2004; Van Regenmortel, 2007).

It is nowadays commonly believed that rational design offers the best prospects for developing new drugs and vaccines (Branrew and Perrie, 2005; D’Argenio and Wilson, 2010) and that this approach is vastly superior to the empirical screening and trial-and-error strategies used in the past. It has been claimed, for instance, that “One of the goals of research in biotechnology is to transform the process of developing a drug from a trial-and-error empirical operation into a rational, structure-based process” (Amzel, 1998). This denigration of empiricism contradicts the fact that even if a molecule or a vaccine has been designed following structure-based predictions, it is still necessary to screen and verify its activity in the biological context in which it is to be used. The label “rational” applied to modern vaccine design is similar to the concept of “rational drug design” which describes the structure-based strategy used in drug development (Kuntz, 1992). This strategy relies on knowledge of the 3D structure of a biological target for predicting and designing candidate molecules that will bind with high affinity and selectivity to the target and inhibit its biological activity. This computer-assisted strategy based on structural bioinformatics and molecular docking has been highly successful, for instance, for developing the antiretroviral drugs that are used to inhibit various HIV enzymes (Wlodawer, 2002; De Clercq, 2009; LaFemina, 2009).

In the biochemical and biomedical literature, the term rational is used to refer to any procedure that is based on the common sense decision to focus on elements of the system under study for which molecular information is available (Obaid et al., 1999; Van Regenmortel, 1999). “Rational” is then synonymous with “reasonable” or “intelligent” and does not correspond to the notion of rationality found in the philosophy of science and which is used in statements such as “scientific judgment is guided by rationality” (Newton-Smith, 1981; Giere, 1988). It has been suggested that rationality should no longer be used as the ultimate justification for scientific procedures and decision making and that it may be preferable to replace it by the concept of “bounded rationality” (Gigerenzer and Selten, 2001; Lucas and Roosen, 2010). Bounded rationality recognizes that when scientists have to reach decisions on how to proceed, they operate under three unavoidable constraints linked to (1) the limited information they have, (2) the limited capacity of their minds to process huge amounts of data, and (3) the limited amount of time they have to make a decision. One consequence of these limitations is that it is then no longer feasible for them to achieve the optimization process that in principle is required from a genuinely “rational” design procedure.

There is one additional reason for being skeptical of the claim that the rational design of vaccines is a realistic endeavor. Although it is possible to rationally design an epitope or antigen so that it will have an improved structural complementarity to one particular nMab, this only represents antigen design in the context of a single epitope–paratope pair and it should not be called immunogen design. When authors discuss the rational design of an HIV-1 vaccine (Hudson et al., 2006; Walker and Burton, 2010; Nabel et al., 2011), they only refer to studies that improve the degree of complementarity in one epitope–Mab pair and they do not clarify how an improved antigen could actually be “designed” to become an immunogen capable of generating protective antibodies. Presumably this would require an investigation of the numerous factors, extrinsic to epitope–paratope recognition, that originate in the immunized host and control the type of protective immune response that a vaccine immunogen is expected to elicit. Optimizing the binding activity of an antigen by structure-based design is clearly not equivalent to controlling or improving by trial-and-error the numerous biochemical and cellular interactions involved in the generation of a neutralizing immune response. Antigen design is actually masquerading as immunogen design because of the unacknowledged, implicit assumption that antigenic reactivity necessarily entails an immunogenic capacity to produce antibodies similar to the one used as template for designing the antigen. Although some authors acknowledge the difference between antigenicity and immunogenicity, they still tend to adhere to the view that an antigen designed to fit an nMab will also be an efficient vaccine immunogen able to elicit neutralizing and protective antibodies. All the experimental immunization results obtained so far (Van Regenmortel, 2011a) as well as the nature of the biological
processes and mechanisms underlying antibody synthesis and maturation speak against such an assumption (Verkoczy et al., 2011; Chen et al., 2012). It is therefore not astonishing that all the studies reporting the successful rational design of a viral antigen have failed to demonstrate that the engineered antigen is also an effective vaccine immunogen (Van Regenmortel, 2012).

**REVERSE VACCINOLOGY AND THE RATIONAL DESIGN OF HIV-1 ANTIGENS**

The concept of reverse vaccinology (RV) was introduced in the field of bacterial vaccines by Rappuoli (2001) about 10 years ago. RV does not attempt to develop vaccine candidates by the usual approach of fractionating bacterial extracts and determining which antigens are able to induce a protective immune response but by predicting potential vaccine immunogens using bioinformatics analyses of entire bacterial genomes. In silico analysis of the genome provides a list of all the surface-exposed proteins that the pathogen is able to express and these proteins are then produced by high-throughput technologies and tested for their immunoreactivity with patient sera as well as for their ability to induce protective antibodies (Rappuoli and Bagnoli, 2011). This strategy was called “reverse” vaccinology because the investigators operate in a so-called reverse manner, i.e., starting from the genome rather than from the organism, to discover which proteins are potential vaccine immunogens. This genome-based strategy has the advantage that hundreds of bacterial proteins are identified as candidate immunogens even if the bacteria cannot be cultivated.

In virology, RV has a different meaning altogether and refers to the strategy of generating a vaccine from the known crystallographic structure of nMabs bound to viral epitopes. The term “reverse” is used metaphorically in the sense that the investigator is trying to generate a vaccine starting from neutralizing antibodies instead of trying to generate such antibodies by immunization (Burton, 2002; Walker and Burton, 2010). It is not clear, however, which vaccine discovery process is being reversed since the bnMab is simply used as a template to reconstruct its epitope outside the context of the natural antigen, using structure-based design technology. The assumption is then made that the reconstructed antigen designed to fit the bnMab will possess the immunogenic capacity of inducing a polyclonal antibody response with the same neutralizing capacity as the Mab.

Since the RV approaches used for developing bacterial and viral vaccines are completely different it would be preferable to call them genome-based and structure-based RV, respectively (Van Regenmortel, 2011b). Both strategies require trial-and-error experimentation to ascertain which candidate bacterial or viral proteins are able to act as effective vaccine immunogens, and it is therefore misleading to present RV as a rational design procedure that overcomes the empirical nature of all vaccine science (Mascola, 1999; Karlsson-Hedestam et al., 2008). In section “Human Intentionality and Rational Design Strategies”, it was argued that the development and discovery of vaccine immunogens by rational design is actually a misnomer. The ensuing discussion will therefore only consider attempts to rationally design antigens able to bind Abs without making the assumption that what is being designed is also a vaccine immunogen (Sattentau and McMichael, 2010).

In a recent comprehensive review paper entitled: “Structure-based vaccine design in HIV: blind men and the elephant,” Pejchal and Wilson (2010) referred to the Indian tale of three men trying to describe an elephant and reaching different conclusions because they touch different parts of the animal. They compared this unsatisfactory procedure to the way investigators try to identify potential HIV vaccine targets by determining which Env regions are targeted by individual nMabs. An amusing illustration of this approach is shown in Figure 3 where one vulnerable “epitopic” region in the animal has been hit by a single Mab arrow.

The question of whether an effective vaccine can be developed by focusing the immune response on a single vulnerable site or epitope is a controversial issue (Scheid et al., 2009; Walker et al., 2009, 2010; Lynch et al., 2011; Moore et al., 2011). An alternative approach is depicted in the painting of Mantegna (Figure 4) which illustrates symbolically that an effective vaccine may require multiple vulnerable regions to be targeted by a polyclonal Ab response (Doria-Rose et al., 2012).
FIGURE 4 | The painting of St Sebastian by Mantegna in the Ca d’Oro museum in Venice. The arrows symbolize a polyclonal antibody response which is not directed to a single vaccine target.

Although the advent of Mabs has revolutionized our understanding of immunochemistry by making it possible for investigators to successfully dissect polyclonal Ab responses in terms of single epitope-paratope interactions, the use of Mabs also had the unfortunate consequence that vaccine hunters have tended to focus on individual epitopes as elicitors of neutralizing Abs. This led them to neglect the synergistic effects that result from the collective neutralizing activities of antibodies directed to different epitopes (Laal et al., 1994; Mascola et al., 1997; Zwick et al., 2001; Van Regenmortel, 2012).

Attempts to design improved HIV-1 antigens have used as templates a small number of nMabs that recognize different antigenic sites of the Env protein such as the conserved CD4-binding site (CD4bs; Burton et al., 1994; Kwong et al., 1998; Zwick et al., 2003; Li et al., 2007), the CD4-induced (CD4i) antigenic site that becomes accessible after gp120 interacts with CD4 (Laherij et al., 2003), the semiconserved V3 loop (Javaherian et al., 1998; Zolla-Pazner, 2004; Zolla-Pazner and Cardozo, 2010), the membrane-proximal external region (MPER) antigenic site (Zwick, 2005), and the glycan antigenic site (Scanlan et al., 2002; Pantophlet, 2010). It must be emphasized that each antigenic site harbors a large number of different epitopes. This means that if an immune response directed to one HIV-1 antigenic site is considered to represent a single specificity, this does not exclude that a large number of different Abs will recognize overlapping targets within the same antigenic region (Walker et al., 2010).

Various strategies have been used to improve the antigenic reactivity of the epitopes recognized by Mabs by reconstructing the epitopes outside the viral protein context in which they occur. Such strategies include (1) hyperglycosylation (Pantophlet et al., 2003a), (2) amino acid substitutions (Pantophlet et al., 2003b), (3) stabilization of the CD4-bound state by introducing cross-links or deleting variable loops (Dey et al., 2007; Zhou et al., 2007; Wu et al., 2010), and (4) immunofocusing, i.e., decreasing the ability of the CD4bs to bind to non-neutralizing antibodies while retaining the capacity to bind to bnMabs (Pantophlet and Burton, 2003). Although some of the engineered antigenic sites that were obtained reacted better with bnMabs, none of them were found to be effective immunogens able to induce broadly neutralizing antibodies (Pejchal and Wilson, 2010; Kong and Sattentau, 2012; Van Regenmortel, 2012).

Attempts were also made to improve the antigenic reactivity of the MPER continuous epitopes recognized by Mabs 2F5, 4E10 (Muster et al., 1993; Julen et al., 2008) and Z13 (Nelson et al., 2007). This was done by adding flanking residues to the core epitopes (Tian et al., 2002), constraining the epitopes in various conformations (Joyce et al., 2002; Ho et al., 2005), mimicking the conformation of the epitopes when they are bound to bnMabs (Ofek et al., 2004), and grafting the epitopes into various protein scaffolds (Arnold et al., 2009; Burton, 2010; Correia et al., 2010; Ofek et al., 2010a; Guenaga et al., 2011). Some of these modifications increased the binding capacity of the peptides but they did not endow them with the capacity to elicit bnAbs (Law et al., 2007; Guenaga et al., 2011). This may be due to the fact that the short core peptide regions recognized by 2F5, 4E10, and Z13 do not constitute the full epitopes since there is evidence that the epitopes are chemically heterogeneous and include lipid moieties that participate in the binding reaction through hydrophobic interactions (Scherer et al., 2010; Ofek et al., 2010b). Other composite HIV epitopes have been shown to include glycan moieties (McLellan et al., 2011). It has been shown that hydrophobic residues of the long CDR H3 loop of Mab 2F5 are able to insert into the viral membrane, producing major conformational rearrangements in both epitope and paratope and illustrating the role of induced fit dynamics in antigen–antibody interactions (Alam et al., 2009; Kim et al., 2011).

Epitopes in certain HIV-1 strains may become inaccessible to antibodies following hyperglycosylation, mutations or conformational changes, a phenomenon called antigenic masking.
Van Regenmortel

Reductionist thinking in HIV vaccinology

Azoitei et al., 2011a). They were shown to be present in HIV-1 gp120 trimers only fairly recently (Van Regenmortel, 2012). Many attempts have been made to develop vaccine immunogens by expressing surface loops containing continuous epitopes of different viruses as recombinant proteins (Hofnung and Charpentier, 2010) although they do not use their protruding loops to reconstruct HIV-1 neotopes that remain unmasked in many HIV-1 strains and are recognized by bnMabs have been identified using signature motifs of 2–4 residues and it has been suggested that cocktails of such epitopes may be good vaccine candidates (Agrawal et al., 2011). Recently, it was shown that cross-clade nAbs could be induced by using V3-scaffold immunogens in a DNA prime/boost regimen (Zolla-Pazner et al., 2011).

An even more difficult task is to reconstruct epitopes that arise from the quaternary structure of viral proteins. It has been known for more than 40 years that such epitopes which were initially called neotopes (see Van Regenmortel, 2009a, 2012) are present in capsid and membrane proteins and are easily detectable by appropriate immunosays (Neurath and Rubin, 1971; Van Regenmortel and Neurath, 1985). These epitopes are nowadays commonly referred to as quaternary epitopes which is a somewhat odd terminology since it would correspond to calling continuous and discontinuous epitopes, primary and tertiary epitopes, respectively. Neotopes arise from the juxtaposition of residues in neighboring protein subunits or from conformational changes induced by intersubunit interactions (Van Regenmortel, 2009b). They were shown to be present in HIV-1 gp120 trimers only fairly recently although they appear to be very common (Broder et al., 1994; Cho et al., 2000; Walker et al., 2009; Pantophlet, 2010; Robinson et al., 2010; Zolla-Pazner and Cardozo, 2010; Pancera et al., 2010; Wu et al., 2011a).

Mab 2902 is the first antibody directed to a neotope of the Env protein which had its structure elucidated (Gorny et al., 2005; Kimura et al., 2009). This antibody which is highly strain-specific has a 21-residue long CDR H3 loop which protrudes from the paratope surface and recognizes a neotope comprising portions of the V2 and V3 loops (Honnen et al., 2007; Changela et al., 2011). The two somatically related Mabs, PG9 and PG16 which neutralize about 80% of primary HIV-1 isolates also recognize a V2/V3 neotope (Walker et al., 2009; Pejchal et al., 2010; Pancera et al., 2010). The PG9 neotope contains a single P strand and two glycans that form a canyon structure into which the long CDR H3 loop of Mab PG9 inserts itself (McLellan et al., 2011). Many anti-HIV-1 antibodies have been found to possess long CDR H3 regions (Stanfield et al., 2004; Huang et al., 2005; Burke et al., 2009; Changela et al., 2011) although they do not use their protruding loops to reach recessed epitopes in the same way as Mabs PG9 and 2909.

Unfortunately, it is not known how antibodies with long CDR H3 loops can be induced by immunization. Reconstructing HIV-1 neotopes by structure-based design may turn out to be an impossible task, partly because of the unstable and transient conformation of Env trimers (Du et al., 2009) which can alternate between open and closed quaternary conformations (Harris et al., 2011). It remains unclear whether such transient neotopes are advantageous for inducing neutralizing antibodies because their conformational variability is able to facilitate induced fit adjustments and BCR recognition. In studies with other HIV-1 epitopes, there are conflicting reports on whether immunogenicity is enhanced by increasing or decreasing epitope flexibility (Dey et al., 2009; Misseri et al., 2010; Ofek et al., 2010a; Guenaga et al., 2011).

In recent years, large numbers of additional bnMabs have been isolated from HIV-1 infected individuals (Scheid et al., 2009; Stamatatos et al., 2009; Corti et al., 2010) which demonstrates that the human immune system is able to induce such neutralizing antibodies more frequently than previously thought (Wu et al., 2010; Scheid et al., 2011; Tomaras et al., 2011; Overbaugh and Morris, 2012). This has led to the expectation that additional HIV-1 epitopes and potential vaccine targets will continue to be discovered and that this should facilitate and guide the design of effective vaccine immunogens (Sattentau and McMichael, 2010). Such optimism assumes that the identification of additional HIV-1 epitopes somehow entails that there is then an increased probability that the rational design of HIV-1 vaccine immunogens will become more feasible. It would be equally unwarranted to claim that discovering additional bnMabs useful for passive immunotherapy is likely to improve our ability to determine which immunogens are able to elicit such protective antibodies by active immunization. Although the passive administration of rare human anti-Env bnMabs to non-human primates (NHPs) can protect the animals from virus infection, this type of successful immunotherapy does not in any way tell us how such protective antibodies can be elicited by vaccination. It is of course possible to improve the paratope binding efficacy of a particular Mab intended for passive immunotherapy, using structure-based design. However, as discussed in section “Human Intentionality and Rational Design Strategies”, what is not feasible is to rationally design an immunogen that will elicit a protective polyclonal antibody response of predetermined efficacy (Van Regenmortel, 2012).

THE BOTTLENECK OF ANTIBODY AFFINITY MATURATION

Considerable knowledge is available regarding the genetic basis of antibody diversity. It has been known for many years that initial exposure to any antigen elicits a primary immune response characterized by low-affinity germline-encoded antibodies (Marka, 1994). In naïve human individuals who have not yet encountered a viral antigen, a primary response is initiated when the antigen binds to germine BCRs derived by random genetic recombinations from a small pool of variable (V), diversity (D), and joining (J) gene segments present in the human genome (Arnaout et al., 2011). These BCRs which arise from rearranged heterodimers of light and heavy chains are highly polyspecific and react weakly with a large number of different antigens, allowing the immune system
to initiate a response against virtually any antigen. Structural analyses have shown that the polyreactivity of germline Abs is enhanced by the flexibility and conformational versatility of the CDRs (Manivel et al., 2000, 2002; James et al., 2003; Yin et al., 2003; Khan and Salunke, 2012). The polyreactivity of germline Abs and of the initial response to HIV-1 Env antigens is a general property of the human immune system and is not a special feature of HIV immune responses. HIV-1 antibodies have been shown to cross-react with cardiolipin (Haynes et al., 2005a), host cell and gut flora antigens (Liao et al., 2011), as well as with histones, ribonucleoprotein, centromere B, and Ro/Sjogren syndrome autoantigen (Morris et al., 2011). It has been postulated that B cells that produce autoreactive Abs may trigger tolerance mechanisms which could eliminate bnAb precursors (Haynes et al., 2005b).

After initial binding of the antigen to germline BCRs, a stochastic process of somatic hypermutation occurs in the variable regions of Ig genes at rates several logs higher than in other genes. This leads to the selective expansion of B cell clones that possess high affinity BCRs for the immunizing antigen and to the proliferation of plasma cells that secrete antibodies with increased affinity for the antigen.

Advances in large scale pyrosequencing of the antibodyome, i.e., of the complete set of antibody sequences present in an organism at a given time, has allowed deep sequencing of V(D)J gene segments and Ig genes (Fischer, 2011). This made it possible to identify which germline Ig genes are used in a given B cell maturation process and to follow the mutational pathway from naive, low affinity B cells to high affinity mature BCRs and antibodies (Dimitrov, 2010).

Early studies of antigen-driven maturation in HIV-1 antibodies showed that extensive somatic hypermutation occurred in their variable regions amounting to an average mutation frequency of 10–20% (Andris et al., 1991; Moran et al., 1993; Huang et al., 2004). When the germline predecessors of the affinity-matured HIV-1 Mabs b12, 2D12, and 2F5 were examined, it was found that the antibodies derived from naive B cells did not bind to the epitopes that were recognized by mature Mab2F5 and 4E10 but these were unable to elicit neutralizing activity of Mab 2F5 and 4E10 but these were unable to elicit neutralizing activity of matured BCRs do not exist in naïve, vaccinated individuals (Dimitrov, 2010).

Attempts are currently being made to try to modify Env molecules so that they become able to bind germline BCRs or maturation intermediates (Wu et al., 2011b). Glycan-depleted Env molecules have been obtained that bind to unmutated precursors of Mab 2F5 and 4E10 but these were unable to elicit neutralizing antibodies (Ma et al., 2011).
cells (Van Regenmortel, 2010b; O’Malley and Dupret, 2005; Mascagni, 2008).

Systems biology is an attempt to describe the multiple interactions between all the parts of a biological system by focusing on the dynamics of the entire system (Ideker et al., 2001; Kitano, 2002). Since the immune system utilizes the dynamic interaction of a wide array of biomolecules, cells, and tissues, the resulting complexity makes the study of immune responses particularly apt to a systems biology approach (Adenot and Smith, 2004). Genomics, proteomics, and other “omics” technologies based on multiplex microarrays, high-throughput sequencing, and bioinformatics are the methods used for this purpose which have made it possible, for instance, to identify candidate antigens for diagnostic, therapeutic, and vaccine applications (Van Regenmortel, 2007). Systems biology is sometimes criticized for being a data-driven approach that cannot lead to the scientific discoveries that follow from hypothesis-driven research (Allen, 2001; Wilkins, 2001) although some authors argue that both approaches are complementary (Kell and Oliver, 2004). It has been suggested that because living organisms have evolved, in response to changing environments, through the accumulation of random, error-prone changes, they developed a type of complexity different from the complex law-like behavior of their underlying physico-chemical constituents (Kelley and Scott, 2008). Biological science therefore does not exhibit the regularities found in the physical sciences and biologists are only able to explain phenomena by positing mechanisms and making predictions without actually offering explanations of how the mechanisms under investigation function. This has led many biologists to adhere to a viewpoint called “epistemological antireductionism” (Nagel, 1998) and to opt for some form of holism, emergentism (Gatherer, 2010), or relational biology (Rosen, 1991; Cornish-Bowden, 2006), while at the same time accepting that many biological phenomena are too complex to be comprehended by human intelligence (Gannoun, 2007).

In vaccinology, systems biology approaches have been used mainly for predicting vaccine-induced immunity (Pulendran et al., 2010; Oberg et al., 2011). A proof-of-concept study was done by identifying patterns of upregulated gene expression, called molecular signatures, that were induced in humans vaccinated with the yellow fever vaccine YF-17D (Querec et al., 2009). This vaccine is one of the most successful vaccines ever developed and it was possible to correlate parameters such as magnitude of antigen-specific CD8+ T cell responses and several molecular signatures with the development of protective immunity against yellow fever. A major shortcoming of such studies is that it is very difficult to establish if any correlations revealed by genomics or proteomics analyses are causally linked to protection. Genomics analyses may reveal, for instance, that following an immunization protocol, hundreds of genes are up- or downregulated. However, since several gene products are always act in combination to generate biological functions, the resulting functional diversity is truly staggering, leading to numbers of potential combinations of causal factors that are larger than the total number of atoms (10^99) in the Universe (Feynman et al., 2005; Noble, 2006).

It should also be evident that the presence of immune correlates of protection in vaccines can only be identified retrospectively after an effective vaccine has been developed empirically. In individuals who have survived a natural infection and are protected against reinfection, it could also be feasible to look for immune correlates of protection. However, this is not possible in the case of HIV infection since there are no individuals who have cleared infection and are subsequently immune to reinfection. Studies with long-term non-progressors and elite controllers of HIV-1 infection (Okulicz, 2012) are also of little value since it is not possible with such individuals to exclude an innate or genetic predisposition to non-infection nor to predict which effector functions would be mediated by an adaptive vaccine-induced immunity (Koup et al., 2011). Since it is also impossible to determine immune correlates of protection from failed HIV-1 vaccine trials, it is not astonishing that past attempts to identify such correlates have been unsuccessful. The recent RV144 vaccine trial which showed a modest level of efficacy (Rerks-Ngarm et al., 2009) is the first instance when it became possible to test if immunological assays could serve as surrogate endpoints for HIV-1 infection (Nakaya and Paleadrang, 2012; Rolland and Gilbert, 2012). However, the RV144 trial was not designed to identify immune correlates of protection and a retrospective analysis of the small number of samples available from this low efficacy trial was unlikely to reveal which aspects of the antibody response correlated with immune protection (Koup et al., 2011). Only the presence of IgG antibodies to the V1/V2 loops was found to show some correlation with a limited protection against HIV infection in the first year of the trial.

The use of NHP models of HIV infection such as simian immunodeficiency virus (SIV) and simian-HIV virus (SHIV) for evaluating immune correlates is also unsatisfactory because of the differences in disease pathogenesis and immune responses in HIV, SIV, and SHIV infections (Koup et al., 2011). It is also no longer generally accepted that showing protection in NHPs should be a gatekeeper for advancing a particular vaccine product into human efficacy trials (Shedlock et al., 2009; Thomas, 2009; Greek, 2012). A particular product that works in macaques may not work in humans and a strategy that shows no efficacy in NHPs could nevertheless work in humans. Animal models are poor predictors for human responses partly because results depend on the viral strains and dosing used for challenge experiments and on the routes of infection (Thomas, 2009). Although it may theoretically be justified to pursue exploratory small-scale human trials when no evidence is available to show that the approach being tested works in NHPs, it is recommended that NHP studies should always be used in the preclinical evaluation of HIV-1 vaccines (Morgan et al., 2009).

SCIENTIFIC UNDERSTANDING ARISES FROM THE ABILITY TO SUCCESSFULLY MANIPULATE THE IMMUNE SYSTEM

In recent years, many authors have stressed the need to embark on large scale basic research programmes in order to increase our understanding of the human immune system and of HIV-1 antigenic structure and pathogenicity (Thomas, 2009; McElrath and Haynes, 2010; Virgin and Walker, 2010). Such recommendations arise from the realization that our current scientific knowledge is too limited to enable us to instruct the human immune system to generate a protective response against HIV-1 infection. It is not clear, however, whether an increase in our basic knowledge
of immunology and of the way bnAbs develop in certain HIV-1 infected individuals will enable us to elicite such antibodies by vaccination.

Instead of emphasizing the importance of theories and basic knowledge for achieving scientific understanding and solving problems in applied science, Hacking (1983) in his influential book Representing and Intervening, suggested that it is the ability of experimentalists to successfully manipulate a given system that gives them the confidence that their scientific constructs and entities are real and that a particular scientific explanation is adequate. Whereas observation alone does not justify a belief in the reality of an invisible fuzzy entity such as an epitope, it is our ability to successfully manipulate it in an experiment that convinces us that the entity exists. In other words, we need to interfere with the material world in order to obtain knowledge about it and our scientific understanding increases because we are able to intervene in a system and successfully manipulate the phenomenon under investigation (Kelley and Scott, 2008). This means that we “understand” the immune system when we can manipulate and control it and are able, for instance, to achieve protective immunity by vaccination (Kumar et al., 2012). An understanding of the immune system is thus achieved because of a prior successful intervention. This is different from the usual assumption that we need to increase our understanding of basic immunology in order to be able to manipulate and control the immune system.

In his book Making Things Happen, Woodward (2003, p. 9) emphasized that causal relations and explanations are important to human beings because of their interest in manipulating and controlling nature. Although the complexity of the immune system may prevent us from identifying all its internal regulatory mechanisms, it is by trial-and-error experimentation that we discover if the system can be successfully manipulated to achieve protective immunity. Unfortunately, there is no guarantee that increasing our knowledge of viral immunology and pathogenicity will necessarily give us that capacity.

Philosophers of science have used the so-called convergence argument to explain why scientists are confident that their experimental results justify a belief in the reality of the entities and phenomena they study (Klee, 1997, p. 212). If a variety of experimental results all converge on establishing what is the cause of AIDS, then it would be perverse to follow AIDS denialists and doubt that HIV causes AIDS. Conversely, it seems odd to believe that the failure of hundreds of attempts to transform HIV-1 epitopes recognized by bnAbs into effective vaccine immunogens is simply a remarkable coincidence which does not demand that we modify our underlying assumptions. It certainly is more realistic to accept that the convergence of so many negative experimental outcomes justifies the conclusion that the RV approach that has been used is not appropriate for developing a preventive HIV-1 vaccine.

CONCLUDING REMARKS

Vaccinologists are well aware that vaccine research is an empirical science (Mascola et al., 1997) and that effective viral vaccines have always been discovered by trial-and-error immunization trials rather than by rational design using the 3D structure of viral antigens. The reasons why successful strategies used in the past failed in the case of HIV are well documented (Hilleman, 1992; Kusters and Almond, 2010; Virgin and Walker, 2008; Kong and Sattentau, 2012; Van Regenmortel, 2012). (1) The natural immune response in HIV-1 infected individuals does not clear the infection and there is therefore no natural immunological mechanism that a vaccine could mimic; (2) during HIV-1 infection, antibodies are mostly elicited against variable and accessible Env loops rather than against functionally important but less accessible conserved domains such as the receptor and co-receptor binding sites; (3) HIV-1 integrates into the host genome and establishes a latent pool of infected cells which conceal the virus from immune recognition; (4) the virus progressively destroys the immune system; (5) HIV-1 isolates exhibit an enormous antigenic variability; (6) the immune system does not readily elicit bnAbs against cryptic and transient HIV-1 epitopes; (7) the degree of antibody affinity maturation required to obtain antibodies that neutralize HIV-1 is much higher than what is needed in the case of antibodies directed to other viruses.

The present review discusses why the reductionist nature of structure-based RV is unlikely to lead to an effective HIV vaccine. Reductionist thinking has been prevalent in molecular biology for half a century and still has a strong hold on investigators who aim to develop a preventive HIV-1 vaccine. The reductionist mindset, for instance, leads them to accept that the biological activities and functions of Abs can be reduced to their physico-chemical structures and that the immunogenic potential of a protein molecule can be deduced from its antigenic properties. Chemical antigenicity is thereby confused with biological immunogenicity. This leads reductionists to assume that it should be possible to control an immune system and have it produce neutralizing antibodies simply by vaccinating an individual with a viral epitope that has been engineered to fit an nMab using structure-based design technology. This assumption overlooks the fact that every anti-HIV-1 bnMab is polyspecific and can bind viral epitopes different from the one identified when the structure of the bnMab-HIV complex was solved. There is therefore no reason why the particular HIV-1 epitope identified by crystallography should be the one that triggered the immune response that gave rise to the Mab.

Since the surface of a viral antigen is an antigenic continuum, the dissection of antigens using individual Mabs tends to give a biased view of immunological specificity and protection against infection since these properties usually result from the collective activities of several different antibodies reacting with the same antigen molecule. By focusing rational vaccine design on single epitope-paratope pairs, the neutralization synergy that tends to occur with polyclonal antibody responses will be missed.

The structural parameters of effective HIV vaccine immunogens have not been elucidated and it is therefore unfortunate that an empirical approach to vaccine development is often denigrated since trial-and-error experimentation remains the best strategy for developing any vaccine.

ACKNOWLEDGMENTS

The author is grateful to Florence Diermer for efficient secretarial assistance and to his grand-daughter Amy Rusch for drawing Figure 3.
REFERENCES

Adenier, A., and Smith, K. D. (2004). A systems approach to dissecting immunity and inflammation. Semin. Immunon. 16, 35–47.

Agnar, A., Hoss, C. E., Swet-
nam, J., Zolla-Pazner, S., and Cardona, Y. (2011). Quantitative assessment of masking of neutralization epitopes in HIV-1. Vaccine 29, 6735–6741.

Alam, S. M., Morelli, M., Domi-
ni, S. M., Litt, H. Z., Zhang, R., Xia, M., Rita-Volkov, S., Sun, L., Harrison, S. C., Hames, B. F., and Chen, R. (2010). Role of HIV-1 membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U.S.A. 107, 20270–20275.

Allen, J. F. (2001). Bioinformatics and discovery: induction heuristics again. Bioessays 23, 304–310.

Al Moudallal, Z., Briand, J. P., and Van Regenmortel, M. H. V. (1992). Monoclonal antibodies as probes of the antigenic structure of tobacco mosaic virus. EMBO J. 11, 1005–1010.

Alm, L. M. (1998). Structure-based drug design. Curr. Opin. Biotechnol. 9, 566–569.

Anders, J. S., Johnson, Z., Zolla-Pazner, S., and Capra, J. D. (1991). Molecular characterization of five human immunodeficiency virus type 1 antibody heavy chains reveals epitope masking typical of an antigen-driven immune response. Proc. Natl. Acad. Sci. U.S.A. 88, 7782–7787.

Arnau, R., Lee, C., Cahill, P., Honan, P. W., Baker, D. K., Strong, R. K., and Schief, R. W. (2011). High-resolution description of antibody-heavy-chain receptors in humans. PloS ONE 6, e28365.

Attili, S. M., Khosravi, P., Holmes, A. K., Witte, T., Geiser, S. C., Phung, P., Yuan, T., Bonsack, D. A., Ma, X., Martin, T. M., Petropoulos, C. J., Tyler, J. W., Katinger, H., and Arnold, F. (2006). Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human thymus cells that display the HIV-1 gpl41 ELKRs epitopes. J. Virol. 80, 5027–5033.

Avetisov, M. L., Correia, B. E., Ran, Y. E., Carocio, C., Kabat, N., Chen, L., Schott, A., Huang, P. S., McIntosh, J. S., Roong, P. D., Rahm, D., Rog, R. K., and Scheif, W. R. (2011). Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 334, 537–539.

Benger, R. (1998). Understanding sci-
ence: why causes are not enough. Phios 65, 339–352.

Bhattacharya, A. K., and Glaude-
mans, C. P. (1978). Dual binding specificities in MOPC 388 and 870 murine myeloma immunoglobulins. J. Immunol. 120, 413–415.

Blackb. J. (1998). Complementarity of peptides specified by “sense” and “antisense” strands of DNA. Trends Biotechnol. 16, 149–154.

Beck, G., and Gersdo, L. (1998). The Com-
text of Reductionism in Biology. Newor-
seau: Federical Symposium No. 213 Chiocchetti Wiley.

Becker, H. R. (2001). Molecular recognition by induced fit: how fit is the concept? News Physiol. Sci. 16, 171–176.

Biezais, M. (2003). Review of What Genes Can’t Do by Lenny Moss. A Bradford Book. The MIT Press, Cambridge, MA. frogs. Nat. Rev. 3, 317–327.

Bromwell, V. W., and Perez, Y. (2005). The rational design of vaccines. Drug Discov. Today 10, 1527–1534.

Brenton, S. (2010). Sequences and con-
siderations. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 365, 207–212.

Broder, C. C., Earl, P. L., Long, D., Arnaud, E. S., Moss, B., and Dennis, R. W. (1994). Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive immune epitope prediction and development of synthetic peptide vaccines. Curr. Med. Chem. 1, 955–964.

Chen, S. W., Van Regenmortel, M. H. V., and Perlak, J. S. (2000). Structure-activity relationships in peptide-antibody complexes: implications for epitope prediction and development of synthetic peptide vaccines. Curr. Med. Chem. 7, 955–964.

Chen, W., Strukower, E. D., Ross, D. E., Feng, Y., Prabakaran, P., and Dimitrov, D. (2002). Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal anti-
todies to viral envelope glycopro-
tic epitopes for mechanisms of immune evasion and design of vac-
cine immunogens. Biotechnol. Bioeng. 83(4), 516–519.

Chen, W. H., Lee, M. R., Chen, C. H., Matthews, T., and Martin, M. A. (2003). Identification of epitope regions targeted by a highly potent monoclonal antibody specific for a poorly neutralizing HIV-1. J. Virol. 81, 2524–2535.

Cheloufi, T., Van Regenmortel, M. H. V., Veron, T., and Atolhah, D. (1996). Functional mapping of conserved residues located at the VL and VH domain interface of a Fab. J. Mol. Biol. 264, 1–6.

Chopra, A., Wu, X., Yang, Y., Zhang, B., Zhu, J., Nardone, G. A., VTIRI, S., Pancera, M., Gentry, M. K., Phoht, S., Robinson, J. E., Stu-
matis, L., Zolla-Pazner, S., Mascola, J. R., and Kalyuzhniy, O. (2011). Crystal-
texture of human immunodeficiency virus type 1 reveals conserved features of qua-
ternary structure-specific antibodies that potentially neutralize HIV-1. J. Virol. 85, 2524–2535.

Crick, F. H. C. (1966). "Of Molecules and Mef. University of Washington Press.

Cunningham, B. C., and Wales, J. A. (1995). Comparison of a structural and a functional epitope. J. Mol. Biol. 254, 588–593.

D'Argenio, D. A., and Wilson, C. R. (2010). A decade of vaccines: inte-
regulation epitopes in MOPC 384 and 870 and selection of monoclonal anti-
to enteric viruses and vaccines. Philos. Sci. 86, 171–173.

Day, E. D. (1998). Advanced Immuno-
ology, 2nd Edn. New York: John Wiley and Sons.

De Cleir, E. (2009). The history of antiviral drug discoveries over the past 25 years. Rev. Med. Virol. 19, 287–299.

Dennaroz, G. F., Dunnet, S. A., and Bruntan, J. L. (2010). Applying bioinformatics for antibody epitope prediction using affinity-sorted monoclonal antibodies for rational vaccine design. Immunity 33, 437–440.

Detrano, M. (2009). The history of antiviral drug discoveries over the past 25 years. Rev. Med. Virol. 19, 287–299.

Dennaroz, G. F., Dunnet, S. A., and Bruntan, J. L. (2010). Applying bioinformatics for antibody epitope prediction using affinity-sorted monoclonal antibodies for rational vaccine design. Immunity 33, 437–440.

D’Argenio, D. A., and Wilson, C. R. (2010). A decade of vaccines: inte-
regulation epitopes in MOPC 384 and 870 and selection of monoclonal anti-
to enteric viruses and vaccines. Philos. Sci. 86, 171–173.

Day, E. D. (1998). Advanced Immuno-
ology, 2nd Edn. New York: John Wiley and Sons.

De Cleir, E. (2009). The history of antiviral drug discoveries over the past 25 years. Rev. Med. Virol. 19, 287–299.
Van Regenmortel Reductionist thinking in HIV vaccinology

Doria-Rose, N. A., Louder, M. K., Yang, E. N., and Chakraborty, A. K. (2006). The rational design of an AIDS vaccine. Science 314, 84–91.

Eisen, H. N. (2006). Rationality: The Adaptive Tool-Box. Chicago: University of Chicago Press, 79–128.

Gorny, M. K., Stamatatos, L., Volsky, B., Pazner, S., and Pinter, A. (2007). The neutralization breadth of HIV-1 type C and related strains. J. Virol. 81, 10535–10540.

Gorny, M. K., Stamatatos, L., Volsky, B., Pazner, S., and Pinter, A. (2007). The neutralization breadth of HIV-1 type C and related strains. J. Virol. 81, 10535–10540.

Gorney, M. K., Stamatatos, L., Volsky, B., Pazner, S., and Pinter, A. (2007). The neutralization breadth of HIV-1 type C and related strains. J. Virol. 81, 10535–10540.

Fenyo, F. T. (2005). The rational design of an AIDS vaccine. Science 314, 84–91.

Fenyo, F. T. (2005). The rational design of an AIDS vaccine. Science 314, 84–91.

Fenyo, F. T. (2005). The rational design of an AIDS vaccine. Science 314, 84–91.

Fenyo, F. T. (2005). The rational design of an AIDS vaccine. Science 314, 84–91.

Fenyo, F. T. (2005). The rational design of an AIDS vaccine. Science 314, 84–91.
Van Regenmortel Reductionist thinking in HIV vaccinology

Kong, L., and Sattentau, Q. J. (2012). Antigenicity and immunogenicity in HIV-1 antibody-based vaccine design. J. AIDS Clin. Res. 38, 303.

Krug, R. A., Graham, B. S., and Droux, D. C. (2011). The quest for a T cell-biased immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol. 11, 65–70.

Kucharski, C., Paini, A., Honnen, W. M., Jorg, M. K., Nurnberg, P. Zolla-Pazner, S., and Krain, S. C. (2005). Antibodies that are cross-reactive for human immunodeficiency virus type 1 (HIV-1) and for influenza virus. Nat Rev Microbiol. 3, 143–155.

LaFemina, R. L. (2009). Structure of human monoclonal antibody 2F5 in human secretions. PLoS Pathog. 5, e1002200. doi: 10.1371/journal.ppat.1002200.

Laure, M., Carlsson, R. M., Wilson, I. A., and Burton, D. R. (2007). Antigenic and immunogenic study of membrane-proximal external region-glycoprotein 120 antigens by a CD4+ prime-boost immunization strategy. J. Virol. 81, 4272–4285.

Lescar, J., Pelligrini, M., Tovar, R., Tsou, H., Poljak, R., Lyson, S. M., Goonetilleke, R., Guo, J., Li, J., and Kim, J. H. (2011). Envelope glycoconjugates protect against HIV: a story of trials and errors. Nat Rev Microbiol. 11, 1033–1034.

Li, Y., Miguélez, S. A., Welch, R., Stobbe, K., Ploug, A., Louder, M. K., Wu, X., Shaw, G. M., Comson, W. M., Wyatt, R., and Mascola, J. R. (2007). Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13, 1033–1034.

Liao, H. X., Chen, X., Manzoni, S., Zhang, R., Marshall, D. J., Vandergraff, N., Whitehead, J. L., Xu, Y., J. S., Huang, K. K., Gao, F., Markowitz, M., Hsu, S. H., Rat, I. J., Goopfert, P. A., Montefiori, D. C., Shaw, G. C., Alam, S. M., Marquilla, D. M., Dunny, T. N., Boyd, S. D., Marshall, E., Egholm, M., Simon, B. R., Hanczakowski, B., Fink, A. Z., Voss, K., Koles, G., Tomaras, G. D., Moody, A. A., Kepler, T. R., and Haynes, B. F. (2011). Initial antibodies binding to HIV-1 gp120 in acutely infected subjects are polyreactive and highly mutated. J. Exp. Med. 210, 2237–2249.

Lucas, E., and Rossen, P. (2010). Emergence, Analysis and Evolution of Structures. Berlin: Springer Verlag.

Lynch, R. M., Rong, R., Belair, S., Sells, A., Li, R., Malungo, J., Allen, S., Robinson, I. E., Granek, S., and Derdeyn, C. A. (2011). The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian woman. J. Virol. 85, 905–915.

Ma, B. J., Alam, S. M., Margolis, D. M., Dunny, T. N., Boyd, S. D., Marshall, E., Egholm, M., Simon, B. R., Hanczakowski, B., Fink, A. Z., Voss, K., Koles, G., Tomaras, G. D., Moody, A. A., Kepler, T. R., and Haynes, B. F. (2011). Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J. Exp. Med. 210, 2237–2249.

Mann, J. F., and Zuckerman, B. (2000). Complexity in biology. EMBO J. 19, 10–14.

McElrath, M. J., and Haynes, R. F. (2010). Induction of immunity against human immunodeficiency virus type 1 by vaccination. Immunology 133, 542–554.

McKearn, J. S., Pancora, M., Carrico, C., Gorman, J., and infections of HIV-1 by vaccination. Immunity 133, 542–554.

McKearn, J. S., Pancora, M., Carrico, C., Gorman, J., and infections of HIV-1 by vaccination. Immunity 133, 542–554.

McKearn, J. S., Pancora, M., Carrico, C., Gorman, J., and infections of HIV-1 by vaccination. Immunity 133, 542–554.

Matsuda, A. R., Noji, G. J., and Schuif, W. B., Ward, A. B., Wileson, I. A., and Krong, P. D. (2011). Structure of HIV-1 gp120 V2/V3 domain with broadly neutralizing antibody PG9. Nature 480, 356–363.

Medawar, P. B., and Medawar, J. S. (1978). The Life Science. London: Granada Publishing.

Menjivar, L. E., Gar, S. E., Sheward, D. M., Madiga, M., Ranchale, N., Lai, Z., Honnen, W. E., Noft/home, M., Tumba, N., Hermans, T. Sibeko, S., Milam, R., Abdool Karim, S. S., and domestic anti-HIV immunoglobulin combined with monoclonal antibod- ies 2F5 and 2G12. J. Virol. 71, 7190-7206.

Maynard-Smith, J. (2000). The concept of information in biology. Phil. Sci. 67, 179–194.

Mayr, E. (1966). Cause and effect in biology. Science 154, 1501–1506.

Mazzocchi, F. (2008). Complexity in biology. EMBO J. 19, 10–14.

McElrath, M. J., and Haynes, R. F. (2010). Induction of immunity against human immunodeficiency virus type 1 by vaccination. Immunology 133, 542–554.

McKearn, J. S., Pancora, M., Carrico, C., Gorman, J., and infections of HIV-1 by vaccination. Immunity 133, 542–554.

McKearn, J. S., Pancora, M., Carrico, C., Gorman, J., and infections of HIV-1 by vaccination. Immunity 133, 542–554.

McKearn, J. S., Pancora, M., Carrico, C., Gorman, J., and infections of HIV-1 by vaccination. Immunity 133, 542–554.

McKearn, J. S., Pancora, M., Carrico, C., Gorman, J., and infections of HIV-1 by vaccination. Immunity 133, 542–554.
Van Regenmortel
Reductionist thinking in HIV vaccinology

Williamson, C., Pinter, A., Morris, L., and CAPRISA 002 Study. (2011). Potential and broad neutralization of HIV-1 subtype C by plasma antibodies targeting quaternary epitopes including residues in the V2 loop. J. Virol. 85, 5128–5141.

Moore, J. P., and Ho, D. D. (1993). Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67, 863–875.

Monden, M. I., Andreu, X. J., Matsunuma, Y., Capra, J. D., and Hersh, E. M. (1993). Variable region genes of anti-HIV human monoclonal antibodies: non-restricted use of the V gene repertoire and extensive somatic mutation. Mol. Immunol. 30, 1543–1552.

Morgan, C., Martihs, M., Miller, D., Auver, C.-M., Caset, M., Brossows, B., Fleurs, J., Hargroder, N., Hu, S. L., Johnson, R. P., Lifson, J., Montefiori, D., Moore, J. P., and Ho, D. D. (1993). An optimally constrained V3 peptide backbone is a better immunogen than its linear antibody by antigen-specific single B cell sorting. PLoS Med. 6, e24078. doi: 10.1371/journal.pmed.0024078.

Mouquet, H., Klein, F., Scheid, J. F., Moran, M. J., Andris, J. S., Matlashov, N., Moore, J. P., and Ho, D. D. (1993). What Genes Can’t Do. Cambridge, MA: MIT Press.

Master, T., Stedoll, F., Parchur, M., Tokha, A., Klins, A., Himmeler, G., Bokem, F., and Katinger, H. (1993). A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642–6647.

Nabel, G. J., Kowing, P. D., and Mascola, J. R. (2011). Progress in the rational design of an AIDS vaccine. Philos. Trans. R. Soc. B Biol. Sci. 366, 2793–2806.

Nagel, T. (1998). “Reductionism and logical relativity: no privileged level of causation,” in Reductionism and antireductionism, ed C. J. van Oss and M. & Kegan Paul.

Neurath, A. R. (2008). “Antibody engineering to promote the induction of HIV-neutralizing antibodies.” in Encyclopedia of Immunology, 2nd Edn. Oxford University Press.

Neurath, A. R., and Rubin, B. A. (2008). “Antibody-mediated immunity to viruses,” in Microbiology in the Twenty-First Century, ed A. K. Das (Calverton, MD: ASM Press), 255–337.

Neurath, A. R. (2008). “Antibody-mediated immunity to viruses,” in Microbiology in the Twenty-First Century, ed A. K. Das (Calverton, MD: ASM Press), 255–337.

Nelson, J. D., Brunel, F., Jensen, R., Crocke, E. T., Cardoso, R. M., Wang, M., Hozel, A., Wilson, J. A., Bradley, J. M., Downs, P. E., Burton, D. R., and Zwick, M. B. (2007). An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1gp120 recognizes an epitope between those of 2D6 and 4830. J. Virol. 81, 4015–4023.

Noble, A. R. (2008). “Antibody-mediated immunity to viruses,” in Microbiology in the Twenty-First Century, ed A. K. Das (Calverton, MD: ASM Press), 255–337.

Noble, A. R., and Ruben, B. A. (1979). Viral Structural Components as Immunogens of Prophylactic Vaccines. Monographs in Virology. Basel: Karger.

Noble, A. R., and Ruben, B. A. (1979). Viral Structural Components as Immunogens of Prophylactic Vaccines. Monographs in Virology. Basel: Karger.

Noble, D. (2008). “Immunoglobin structure and function,” in Immunochemistry, ed C. J. van Oss and M. H. V. Van Regenmortel (Amsterdam: Elsevier), 361–375.

Noble, D. (2006). The Johns Hopkins University. Cold Spring Harb. Symp. Quant. Biol. 71, 1279–1286.

Noble, D. (2008). “Immunoglobin structure and function,” in Immunochemistry, ed C. J. van Oss and M. H. V. Van Regenmortel (Amsterdam: Elsevier), 361–375.

Noble, D. (2004). “Viral Structural Components as Immunogens of Prophylactic Vaccines.” in Microbiology in the Twenty-First Century, ed A. K. Das (Calverton, MD: ASM Press), 255–337.

Obeid, O. E., Partrick, C. D., Howard, C. R., and Steward, M. W. (1995). Protection against mollivirus-induced encephalitis by immunization with a rationally designed synthetic peptide vaccine containing B- and T-cell epitopes from the fusion protein of measles virus. J. Virol. 69, 1420–1428.

Oberg, A. L., Kennedy, R. B., Li, P., Ofek, G., McKee, K., Yang, Y., Yang, Y., Skinner, J., Guenaga, F., Zwick, R., Zwick, M. B., Nabel, G. J., Mascola, J. R., and Kowing, P. D. (2011b). Structure-function analysis of two quaternary epitope scaffolds. J. Virol. 84, 2953–2962.

Ockel, G., Trash, M., Sanabio, A., Katinger, H., Mascola, J. R., and Kowing, P. D. (2011a). Fine mapping of the interaction of neutralizing and non-neutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 85, 642–658.

Parnes, O. (2004). From incorporation to incorporation: de novo and promiscuous recognition as precursors of a paradigm shift in immunology. Mol. Immunol. 40, 985–991.

Pichil, R., and Wilson, J. A. (2010). “Antibody epitope specificity,” in Vaccines: Principles and Practice, ed E. H. R. L. Phillips, E. R. R. G., and K. C. C. C. (Berlin, Heidelberg: Springer Berlin Heidelberg), 37–53.

Pichil, R., and Wilson, J. A. (2010). Structure-based vaccine design in HIV: blind men and the elephant? Curr. Pharm. Des. 16, 3744–3753.

Pichil, R., Walker, L. M., Stanfield, R. L., Phogat, S. K., Koff, W. C., Pognan, F., Burton, D. R., and Wilson, J. A. (2010a). Structure and function of broadly reactive antibody PG16 revealed an HS subdivision that mediates potent neutralization of HIV-1. Proc. Natl. Acad. Sci. U.S.A. 107, 11483–11488.

Purcell, B., and Li, S., and Nakaya, H. I. (2011a). Systems vaccinology. Immunology 133, 516–529.

Pellino, S. (2002). Causation and Explanation. Chichester and Montreal: Acumen and McGill-Queen’s University Press.

Quince, T. D., Skoriky, S. R., Lee, E. K., Cao, W., Nakaya, H. I., Tawson, D., Pirani, A., Gernert, K., Deng, J., Wu, R., Burton, D. R., and CAPRISA 002 Study. (2011). Progress in the rational design of new vaccine development. J. Virol. 85, 8638–8645.

Quesenberry, R., Olmann Saphire, E., Pognan, F., Burton, D. R., and Wilson, J. A. (2010). Fine mapping of the interaction of neutralizing and non-neutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 85, 642–658.

Rappuoli, R., and Steward, M. W. (1995). “Monomeric gp120 as novel antigens for HIV vaccine design.” in Advances in Experimental Medicine and Biology, ed J. V. Horvath, J. V. H., and R. C. A. R. (New York, NY: Plenum Press), 245–268.

Reid, K., Bagnoli, F., and Bagnoli, F. (eds) (2001). The Encyclopedia of General Virology. A007039. Cambridge: The MIT Press.

Roozendaal, Y., Capra, J. D., and Hersh, E. M. (1993). Reductionist thinking in HIV vaccinology. J. Virol. 67, 863–875.

Rood, M., Andris, J. S., Matlashov, N., Moore, J. P., and Ho, D. D. (1993). An optimally constrained V3 peptide backbone is a better immunogen than its linear antibody by antigen-specific single B cell sorting. PLoS Med. 6, e24078. doi: 10.1371/journal.pmed.0024078.

Rood, M., Andris, J. S., Matlashov, N., Moore, J. P., and Ho, D. D. (1993). An optimally constrained V3 peptide backbone is a better immunogen than its linear antibody by antigen-specific single B cell sorting. PLoS Med. 6, e24078. doi: 10.1371/journal.pmed.0024078.

Rood, M., Andris, J. S., Matlashov, N., Moore, J. P., and Ho, D. D. (1993). An optimally constrained V3 peptide backbone is a better immunogen than its linear antibody by antigen-specific single B cell sorting. PLoS Med. 6, e24078. doi: 10.1371/journal.pmed.0024078.
Van Regenmortel Reductionist thinking in HIV vaccinology

Tartaglia, J., McNeil, J. G., Francis, D. P., Stblton, D., Birx, D. L., Chomot, M., O'Connor, C., Tongsherson, F., Bobb, M. L., Mchale, N. L., Kewal, P., Kim, J. H., and MOPH-TAVG Investigators. (2009). Vaccination with AIDSVAX and ADVAXV to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 360, 2388–2398.

Richards, F. F., Konigsberg, W. H., Rossen, R. W., and Varga, J. M. (1975). On the specificity of antibodies. Science 187, 140–157.

Robinson, J. K., Frano, K., Elliott, D. H., Mhal, M. J., Bena, A., Monforte, D. C., Zolla-Pazner, S., Gorny, M. K., Krak, Z., and Stamatatos, L. (2010). Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in those macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. J. Virol. 84, 3443–3453.

Rolland, M., and Gilbert, P. (2012). Evaluating immune correlates in HIV type 1 vaccine efficacy trials what RT04 may provide. AIDS Rev. Hum. Retroviruses 28, 480–484.

Rose, S. (1998). What is wrong with reductionist explanations of behavior? In The Limits of Reductionism in Biology. Neuros Endowment Sym- posium Nr 213, ed. D. Boeck and J. Goede (Chichester: Wiley), 176.

Rowe, D. W. (1981). New Virological Approaches into the Nature, Origins and Evolution of Life. New York: Columbia University Press.

Rosenberg, A. (1994). Instrumental Science: a review of experimental data and implications. Chicago: Chicago University Press.

Rosenstein, R. W., and Varga, J. M. (2009). Revisiting the central dogma in the 21st century. EMBO Rep. 10, 1516–1520.

Rosen, R. (1991). Instrumental specificity, unique combinations of natural global predictability provide an alternative to the classical concept. J. Virol. 65, 1635–1637.

Shaw, J. E., Leaman, D. P., Zeik, M. R., McMichael, A. I., and Burton, D. R. (2010). Aromatic residues at the edge of the antibody combining site facilitate vir al glycoprotein recognition through membrane interactions. Proc. Natl. Acad. Sci. U.S.A. 107, 1520–1534.

Shellcock, D. I., Shiels, G., and Winter, D. B. (2009). Monoclonal antibodies against HIV vaccines: using macaques to define epitopes for clinical tests. Nat. Rev. Immunol. 9, 717–728.

Shibuchi, Y., Jaoko, W., Sugimoto, S., and Mariano, M. N. (1993). Mosquitoes of antibody affinity by a non-contact reaction. Proced. Soc. 2, 206–214.

Shriver, J. A., Bonser, T., Feldmnn, T., and Kim, K. J. (1985). Mapping epitopes in the insulin molecule using monoclonal antibodies. Eur. J. Immunol. 15, 1884–1890.

Shapiro, J. A. (2009). Revisiting the central dogma in the 21st century. Ann. N.Y. Acad. Sci. 1176, 6–28.

Slack, M. D., Bada, W., Priddle, F. H., Pump, F., Cantow, E., Lauter, D. S., Lohman, J. K., Boan, M., Farruggia, T., Mill, G., Brunski, J., Proietti, A., McPhie, D. A., Manigart, O., Karita, E., Inwoley, J., Askew, W., Deborius, J., Bélanger, L. G., Ritzmann, P., Paris, W., Walker, L. G., Prigord, P., Wiel, T., Fiset, P., Burton, D. R., and Koff, W. C. (2009). Human immunodeficiency virus type 1 epitope neutralization: individual and broad potency neutralizing activity identified by using a high-throughput neutralization assay together with an artificial selection algorithm. J. Virol. 83, 7337–7348.

Spilling, B., Pruesse, T., and Siokind, G. W. (1983). Degeneracy of antibody specificities. J. Immunol. 131, 842–852.

Stamatatos, L., Merin, L., Burton, D. R., and Mascola, J. R. (2009). Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15, 866–870.

Stumph, R. L., Gemm M. K., Williams, C., Zolla-Pazner, S., and Wilson, I. A. (2004). Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-520. Structure 12, 193–204.

Sundberg, E. J., and Mariuzza, R. A. (2002). Molecular recognition in antibody-antigen complexes. Annu. Rev. Immunol. 20, 159–180.

Talmage, D. W. (1999). Immunologi- cal specificity, unique combinations of natural global predictability provide an alternative to the classical concept. J. Virol. 73, 1245–1268.

Thomas, C. (2009). Roadblocks in HIV research few questions. Nat. Med. 15, 875–879.

Tian, Y., Ramesh, C. V., Naqvi, S., Pansl, T., Comai, T., Taccone, M., Diao, K., Cox, T., Arnold, E., Gloyer, G., and Taylor, J. W. (2006). Structure-affinity relationships in the gp120 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chains and backbone modifications and conformational constraints. J. Pep. Sci. 9, 264–278.

Tomanus, G. D., Bailey, J. M., Gray, E. S., Crooks, E. T., Osano, K., Moore, P. L., Tumb, N., Teng, T., Shen, X., Velho, T., Deck, L., Wharten, C. K., Gus, F., Alam, S. M., Easterbrook, P., Abdo, Bakerin, S., Kangano, G., Crump, J. A., Coomb, M., Shaw, G. M., Mascolo, I. R., Haynes, F. B., Monte-, fiori, D. C., and Merio, L. (2011). Polyvalent B cell responses to conserved neutralization epitopes in a subset of HIV-1 infected individuals. J. Virol. 85, 11510–11519.

Tropsha, A., Kiel, S. J., and Chukin, I. M. (1992). Making sense of anorexia is a review of experimental data and developing ideas on sense–antiseense recognition. J. Mol. Biol. 235, 43–54.

VanCott, T. C., Belkis, F. R., Burke, D. S., Koloff, R. R., and Birx, D. L. (1995). Lack of induction of anti- body specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vac- cines. J. Immunol. 155, 4100–4110.

Van Bubnoff, A. (2010). Vaccines to Antivirals: Govt Op. LIVI Report, July–August 2010.

Van Regenmortel, M. H. V. (1998a). Minimum, continuous parameters and hypodiploid complementarity: novel approximations in the description of immunological specificity. J. Immunol. Methods 218, 140–144.

Van Regenmortel, M. H. V. (1999). Molecular design versus empirical discovery in peptide-based vaccine. Coming to terms with fuzzy recognition sites and B-defined structure function relationships in immunol- ogy. Vaccine 18, 210–217.

Van Regenmortel, M. H. V. (2002). Reductionism and the search for structure-function relationships in antibody molecules. J. Mol. Biol. 325, 240–247.

Van Regenmortel, M. H. V. (2003a). “Profile of reductionism in immunology” in Prosems and Limits of Reductionism in the Biomedical Sciences, eds M. H. V. Van Regenmor- tel and D. L. Hall (Chichester: John Wiley).

Van Regenmortel, M. H. V. (2004a). Biological complexity emerges from the ashes of genetic reductionism. J. Virol. 17, 145–148.

Van Regenmortel, M. H. V. (2004b). Reductionism and complexity in molecular biology. Scientists now have the tools to unravel biological complexity and overcome the limitations of reductionism. EMBO Rep. 5, 1010–1015.

Van Regenmortel, M. H. V. (2006). Immunoinformatics may lead to a reappraisal of the nature of B cell epitopes and of the feasibility of synthetic peptide vaccines. J. Virol. 19, 185–187.

Van Regenmortel, M. H. V. (2007). The rational design of biological complex- ity: a deceptive metaphor. Pro- teins 67, 965–975.

Van Regenmortel, M. H. V. (2004a). Synthetic peptide vaccines and the search for neutralization B cell epi- topes. Open Vaccin. J. 5, 33–44.

Van Regenmortel, M. H. V. (2004b). “What is a B cell epitope?” in Epitope: Mapping Protocols, eds U. Reimeke and M. Schorleker (Springer: Heidelberg Press), 5–20.

Van Regenmortel, M. H. V. (2011a). Limitations to the structure- functional design of HIV-1 vaccine immunogens. J. Mol. Biol. 416, 741–753.

Van Regenmortel, M. H. V. (2011b). Two meanings of reverse vaccinology and the empirical design of vaccine science. Vaccine 29, 7975–7977.

Van Regenmortel, M. H. V. (2012). Requirements for empirical immunogenicity trials, rather than...
structure-based design, for developing an effective HIV vaccine. Arch Virol 157, 1–21.

Van Regenmortel, M. H. V., and Hall, D. L. (2002). Protocols and Centers of Reductionism in the Biomedical Sciences. Chichester: John Wiley.

Van Regenmortel, M. H. V., and Muller, S. (1999). Synthetic Peptides as Antigens. Amsterdam: Elsevier.

Van Regenmortel, M. H. V., and Neuraz, A. R. (1985). Immunogenetics of Viruses. Amsterdam: Elsevier.

Verlooy, L., Kaloes, G., Moody, M. A., and Harnes, R. B. (2011). Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol 23, 383–390.

Virgin, H. W., and Walker, B. D. (2010). Immunology and the elusive AIDS virus. Nature 464, 214–224.

Wagner, A. (1999). Causality in complex systems. Biol. Philos. 14, 85–101.

Walker, L. M., and Burton, D. R. (2010). Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 22, 358–366.

Walker, L. M., Phogat, S. K., Chai-Ho, P. Y., Wagner, D., Phung, P., Gou, J. L., Wrin, T., Smek, M. D., Jing, S., Mitchell, J. L., Lehman, J. K., Priddy, F. H., Oun, O. K., Ivory, J. S. M., Hammers, F. W., Protocol G Principal Investigators, Kaminsky, S., Zhang, M., Phogat, S. K., and Burton, D. R. (2009). Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285–289.

Wu, X., Zhou, T., Zhou, L., Zhang, B., Geurzoni, I., Wang, C., Chen, X., Longo, N. S., Lounet, M., McKee, K., O’Dell, S., Perfetto, S., Schmid, S. D., Shi, W., Wu, L., Yang, Y., Zhang, Z., Zheng, Z., Nemezu, D., Wu, X., Yang, Z., Yau, A., Hapin, J. K., Dawson, P. E., Wilson, I. A., and Katinger, H. (2011). Structural determination of a conserved neutralization epitope on HIV-1 gp120. Nature 474, 732–737.

Zhou, Z., Qin, R. H., Chen, W., Zhao, Q., Shen, X., Schrader, K., Wang, Y., Oude, G., Steen, E., Fabris, P., Friday, H. R., Owens, J., Zwick, M. B., Arthos, J., Burton, D. R., Dimitriou, D. S., Saphire, E., Nabholz, G. J., and Koong, P. D. (2007). Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 320, 811–814.

Zhou, Z., Xu, L., Dey, B., Hassall, A. J., Van Byk, D., Xiang, S. H., Yang, X., Zhang, M. Y., Zwick, M. B., Arthos, J., Burton, D. R., Dimitriou, D. S., Saphire, E., Nabholz, G. J., and Koong, P. D. (2007). Structural basis for broad and potent neutralization of HIV-1 by antibody 2F5. Science 319, 595–614.

Zolla-Pazner, S. (2004). Identifying epitopes of HIV-1 envelope sequence-variable regions for use as vaccine design. Nat. Rev. Immunol. 10, 527–535.

Zolla-Pazner, S., Kong, K. P., Jiang, X., Cardoso, T., Naidn, A., Cohen, S., Tomori, M., Soman, M. S., Wang, S., and Lu, S. (2011). Cross-clade HIV-1 neutralizing antibodies induced by VS-pseudotyped protein microarrays following priming with gp120 DNA. J. Virol. 85, 9807–9808.

Zwick, M. B. (2005). The membrane-proximal external region of HIV-1 gp120: a vaccine target worth exploring. AIDS 19, 1725–1737.

Zwick, M. B., Patron, P. W., Saphire, E. O., Ch浠ght, S., Wang, M., Scott, J. K., Dawson, P. W., Wilson, J. A., and Burton, D. R. (2003). Molecular features of the broadly neutralizing immunoglobulin GI b2 required for recognition of human immunodeficiency virus type 1 gp120. J. Virol. 77, 5863–5876.

Zwick, M. B., Wang, M., Phogat, S., Striger, G., Kartung, H., Burton, D. R., and Patreon, P. W. (2001). Neutralization synergy of human immunodeficiency virus type 1 primary isolates is mediated by cocktails of broadly neutralizing antibodies. J. Virol. 75, 12196–12208.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 27 April 2012, accepted: 21 June 2012, published online: 08 July 2012. Citation: Van Regenmortel MHD (2012) New routes of HIV vaccine development by reductionist thinking. Front. Immunol. 3:44. doi: 10.3389/fimmu.2012.00014

This article was submitted to Frontiers in Immunogenetics and Vaccines, a specialty of Frontiers in Immunology.

Copyright © 2012 Van Regenmortel. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.